Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncolytics BiotechONCY -4.67%28 9-Day RSI is 50.93 as of Jul. 16, 2026. GuruFocus rates ONCY with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Oncolytics Biotech ranks worse than 56.54% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Oncolytics Biotech 9-Day RSI Related Terms
ONCY vs VRCA, ENGN, ALDX: 9-Day RSI Comparison
For the Biotechnology subindustry, Oncolytics Biotech's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncolytics Biotech 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Oncolytics Biotech's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolytics Biotech (ONCY) has a 9-Day RSI of 50.93 as of Jul. 16, 2026. According to the industry distribution chart, Oncolytics Biotech ranks #804 out of 1422 companies in the Biotechnology industry, placing it in the top 56.5%.
Is Oncolytics Biotech's 9-Day RSI too high?
Oncolytics Biotech's current 9-Day RSI is 50.93. The Biotechnology industry median 9-Day RSI is 48.66. Oncolytics Biotech's value of 50.93 is 4.7% above this industry median. Based on the distribution chart, Oncolytics Biotech ranks #804 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncolytics Biotech has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's 9-Day RSI compare to VRCA and ENGN?
According to the Biotechnology industry distribution chart, Oncolytics Biotech ranks #804 out of 1422 companies for 9-Day RSI. This places Oncolytics Biotech in the lower half of its industry. The industry median 9-Day RSI is 48.66. Oncolytics Biotech's value of 50.93 is 4.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 48.66, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncolytics Biotech's current 9-Day RSI of 50.93 is 4.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 48.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolytics Biotech's current 9-Day RSI is 50.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current 9-Day RSI of 50.93. The current 9-Day RSI is 50.93 and 4.7% above the Biotechnology industry median of 48.66. Oncolytics Biotech's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current 9-Day RSI is 50.93 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
28GF Score
Get the complete analysis for ONCY
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONCY has been successfully added to your 
